

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2023/077090 A8

(43) International Publication Date
04 May 2023 (04.05.2023)

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/02 (2006.01)
A61P 35/00 (2006.01) A61K 39/395 (2006.01)

(21) International Application Number:

PCT/US2022/078912

(22) International Filing Date:

28 October 2022 (28.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/273,492 29 October 2021 (29.10.2021) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543 (US).

(72) Inventors: **SRIVASTAVA, Shivani**; c/o Bristol-Myers
Squibb Company, Route 206 and Province Line Road,
Princeton, New Jersey 08543 (US). **AGRAWAL, Shru-
tidevi Kunjbiharilal**; c/o Bristol-Myers Squibb Company,
Route 206 and Province Line Road, Princeton, New Jer-
sey 08543 (US). **GELB, Arnold Bruce**; c/o Bristol-Myers
Squibb Company, 1500 Owens Street, San Francisco, Cali-
fornia 94158 (US). **CHEONG, Alicia Mun Yen**; c/o Bris-
tol-Myers Squibb Company, Uxbridge Business Park, San-
derson Road, Uxbridge Middlesex UB81DH (GB).

(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein &
Fox P.L.L.C., 1100 New York Avenue, NW, Washington,
District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,
SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

01 June 2023 (01.06.2023)

(15) Information about Correction:

see Notice of 01 June 2023 (01.06.2023)

(54) Title: LAG-3 ANTAGONIST THERAPY FOR HEMATOLOGICAL CANCER

(57) Abstract: The disclosure provides a method of treating a human subject afflicted with a hematological cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor). In some aspects, the subject is greater than or equal to about 12 years old and has a weight of greater than or equal to about 40 kg, including subjects less than or equal to about 30 years old or less than about 18 years old. In some aspects, the subject has a weight of less than about 40 kg and/or is less than about 12 years old.



WO 2023/077090 A8